What is BioLineRx's gross profit margin?

What factors drove the changes in BioLineRx's revenue and profit?

What does BioLineRx do and what are its main business segments?

What were the key takeaways from BioLineRx's earnings call?

What were the key takeaways from BioLineRx’s earnings call?

What is the revenue and EPS growth rate for BioLineRx year over year?

What is BioLineRx's latest dividend and current dividend yield?

What guidance did BioLineRx's management provide for the next earnings period?

- **GLIX1 Milestone**: GBM Phase I/IIa trial to enroll first patients in March 2026, targeting $3.7B market with 90% cancer coverage.
- **Financial Stability**: $21M cash runway to H1 2027; resolved $7.2M legal claim, freeing resources for R&D.
- **Trial Progress**: CheMo4METPANC trial enrollment accelerating; GLIX1 patent extends to 2040 with broad cancer applicability.
- **Key Risks**: GBM trial focused on safety; no interim efficacy data; APHEXDA sales dependent on Ayrmid's private strategy.

**【CEO Summary Section】**
- **GLIX1 Phase I/IIa Trial Update**: FDA-approved IND for glioblastoma (GBM) trial to commence patient enrollment by end-March 2026. Orphan Drug Designation granted in U.S. and Europe. Phase I aims to establish safety and dose in 30 recurrent GBM patients, with data expected H1 2027. Phase IIa to evaluate efficacy in GBM and other cancers.
- **Market Potential**: GBM incidence ~18,500 in U.S. and 13,500 in EU, addressing $3.7B market. GLIX1's novel TET2-restoring mechanism targets 90% of cancers, with patent protection to 2040.
- **Motixafortide in PDAC**: CheMo4METPANC trial (gemcitabine + cemiplimab) enrollment accelerating; interim futility analysis expected 2026. Positive results could validate combination therapy.
- **Financial Health**: $21M cash as of Dec 2025, sufficient for operations into H1 2027. APHEXDA royalties $1.2M in 2025. Legal victory vs. Biokine resolves $7.2M claim, freeing resources for GLIX1.

**【CFO Financial Commentary】**
- **Revenue**: $1.2M (2025) vs. $28.9M (2024), driven by Ayrmid and Gloria out-licensing. APHEXDA sales $6.5M, generating $1.2M royalties.
- **Expenses**: R&D $8.1M (down 13% vs. 2024), G&A $3.1M (down 51%), reflecting headcount reduction and GLIX1 initiation.
- **Net Loss**: $2M (2025) vs. $9.2M (2024). Cash balance $20.9M, supporting current plan.

**【Q&A Highlights】**
- **GBM Trial Interim Data**: Phase I focused on safety; no efficacy readouts planned. Blood-brain barrier penetration assessment possible via biopsy, but not guaranteed.
- **Physician Enthusiasm**: PIs at NYU, Northwestern, and Moffitt praise GLIX1's novel mechanism and preclinical efficacy.
- **Gloria Updates**: Bridging trial for China approval underway; no 2026 data expected. Solid tumor trials in discussion.
- **Ayrmid Sales Guidance**: Private company未提供, but BioLineRx expects long-term growth in APHEXDA.

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

- **JV glioblastoma drug targets $3.7B market**; **sickle cell trial shows 3x yield**; **cash funds 2027**. 

**【CEO Opening Remarks】**
- Announced JV with Hemispherian for GLIX1 glioblastoma drug, targeting $3.7B market. Phase I/IIa trial starts Q1 2026. 
- Sickle cell trial results show 3x yield vs plerixafor, with $0.4M APHEXDA royalties. Cash of $25.2M funds operations to H1 2027.

**【CFO Financials】
- Q3 net loss $1M (vs $5.8M 2024), R&D down 33%, cash sufficient to 2027. 

**【Q&A Highlights】
- GLIX1 manufacturing secured, 90% of cancers responsive, FDA fast track likely. Sickle cell data to ASH 2025. 


BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

- **Breakthrough PDAC Data**: 64% partial response rate and 9.6-month PFS in Phase IIb trial highlight motixafortide's potential in pancreatic cancer, positioning for regulatory filings.
- **Sustainable Cash Runway**: $28.2 million cash provides 2+ years of funding, supported by 70% expense reduction post-Ayrmid restructuring.
- **Strategic Asset Sourcing**: Targeting early-stage oncology/rare disease assets with clear paths to approval, avoiding upfront payments to maximize capital efficiency.
- **Rare Disease Expansion**: Sickle cell disease trials show superior mobilization rates vs. plerixafor, setting up future milestone revenue streams.

**【CEO Summary Section】**
- **Pipeline Expansion Progress**: CEO highlights ongoing evaluation of early-stage oncology and rare disease assets, targeting a transaction announcement this year. The company is focused on assets with clear clinical development paths, partly funded by Ayrmid and Gloria Bio milestones.
- **APHEXDA Licensing Update**: Retained rights to motixafortide in pancreatic ductal adenocarcinoma (PDAC) and rare disease trials. Q2 2025 royalty revenue from Ayrmid was $0.3 million, with APHEXDA sales of $1.7 million.
- **CheMo4METPANC Trial Success**: Phase IIb trial in PDAC shows 64% partial response rate (6 confirmed), 91% disease control, and 9.6-month median PFS vs. historical 23% response and 5.5-month PFS. Biopsy data show increased CD8+ T cells, indicating immune response enhancement.
- **Sickle Cell Disease Trials**: Two Phase I studies evaluating motixafortide for hematopoietic stem cell mobilization in gene therapy. Data expected H2 2025, with potential for long-term milestones.
- **Financial Strength**: $28.2 million cash runway extended to H1 2027, down from prior guidance of H2 2026. Restructuring reduced operating expenses by 70%, eliminating U.S. commercial operations.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: Total revenue $0.3 million (royalties), R&D expenses $2.3 million (stable vs. Q2 2024), no sales/marketing expenses. Net loss $3.9 million vs. Q2 2024 net income $0.5 million due to one-time costs and headcount reduction.
- **Cost Efficiency**: General & administrative expenses down 87% to $0.2 million, driven by headcount reduction and milestone payments.

**【Q&A Highlights】**
- **Trial Interim Analysis**: Prespecified 40% PFS event interim analysis for PDAC trial expected to provide directional data, but unlikely to support accelerated approval. Full results could be a value inflection point.
- **Asset Sourcing Strategy**: Focused on in-licensing early-stage assets (IND-Phase I) from smaller companies with limited capital, leveraging BioLineRx's development expertise. No upfront payments preferred, with milestones tied to clinical success.
- **Sickle Cell Trial Metrics**: Key endpoints include safety, CD34+ cell mobilization (cells/µL), and collection yield. Historical plerixafor benchmark <100 cells/µL vs. motixafortide median 200-300 cells/µL in early data.
- **Partnership Clarity**: No option rights for Regeneron in PDAC trial; collaboration is purely academic with data sharing post-publication.

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

- **APHEXDA Recovery**: Q1 2025 sales rebound to $1.4M, with $0.3M in royalties, positioning for long-term $100M+ annual royalty potential.
- **PDAC Breakthrough**: Phase 2b trial shows 64% response rate vs. 23%, with interim PFS data due 2026 and full results in 2027.
- **Financial Resilience**: $26.4M cash runway through 2026, 70% cost reduction to $12M annual burn.
- **Pipeline Momentum**: Evaluating 2-3 novel assets for 2025 deal closure, leveraging motixafortide's CXCR4 inhibition in rare diseases.

**【CEO Opening Remarks】**
- Announced successful transition of APHEXDA to Ayrmid Pharma, resulting in Q1 2025 APHEXDA sales of $1.4M and $0.3M in royalties for BioLineRx.
- Highlighted motixafortide's potential in pancreatic cancer (PDAC) with Columbia University's Phase 2b trial showing 64% partial response rate vs. historical 23%, and median PFS of 9.6 months vs. 5.5 months.
- Reduced annual cash burn by 70% to $12M, with $26.4M cash on hand and runway through H2 2026.

**【CFO Financial Update】**
- Q1 2025 total revenue: $0.3M (royalties from Ayrmid) vs. $6.9M in Q1 2024 (upfront payments and product sales).
- R&D expenses: $1.6M (down 36% YoY) due to U.S. commercial operations shutdown.
- Net income: $5.1M (vs. $0.7M loss YoY) driven by warrant revaluation.

**【Q&A Key Highlights】**
- **APHEXDA Long-Term Outlook**: CEO estimates $100M+ annual royalty potential, with 18-23% royalty rate on Ayrmid's sales.
- **PDAC Trial Strategy**: Interim PFS analysis at 40% events (2026) and final OS data (2027) will guide regulatory path; Columbia controls data release timing.
- **Pipeline Expansion**: Actively evaluating 2-3 oncology/rare disease assets, targeting lean clinical pathways; expects 2025 deal announcement.
- **Cell Therapy Integration**: Motixafortide's ability to reduce apheresis sessions could lower gene therapy COGS, with trials in sickle cell disease showing promise.

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

- **Strategic Reboot Success**: $10M upfront + $87M milestones from Ayrmid deal, cutting cash burn 70% to $12M/year.
- **Clinical Momentum**: PDAC trial expands to 108 patients; sickle cell trials show single-cycle stem cell collection feasibility.
- **Financial Health**: 2024 revenue up 502% to $28.9M, net loss down 85% to $9.2M, with $29M runway to 2026.
- **APHEXDA Growth**: 10% U.S. market share in 11 months, transitioning to Ayrmid for sustained expansion.

**【CEO Strategic Overview】**
- Announced a major strategic shift in November 2024 with the licensing agreement with Ayrmid Pharma for motixafortide (APHEXDA), generating $10 million upfront payments and potential $87 million in milestones.
- Streamlined operations reduced annual cash burn by 70% ($40M to $12M), with $29M pro forma cash runway through H2 2026.
- Focused on in-licensing early-stage oncology and rare disease assets, with active discussions and plans to announce deals in 2025.

**【CFO Financial Highlights】**
- 2024 Total Revenue: $28.9M (502% YoY growth), driven by $15M from licensing agreements and $6M APHEXDA sales.
- Net Loss: $9.2M (85% YoY reduction), reflecting cost-cutting and one-time gains.
- R&D Expenses: $9.2M (26% YoY decline), Sales & Marketing: $23.6M (6% YoY decline).

**【Key Pipeline Updates】**
1. **PDAC Program (CheMo4METPANC Trial):** Expanded to 108-patient randomized Phase 2b with PFS as primary endpoint. Enrollment expected to complete by 2027.
2. **Sickle Cell Disease Trials:**
   - WashU trial showed median CD34+ cells of 200/µL, enabling single-cycle collection for gene therapy.
   - St. Jude trial dosed first patient Q1 2025, targeting multi-cycle reduction.
3. **APHEXDA Commercialization:** 10% U.S. market share in CXCR4 inhibitors within 11 months, transitioning to Ayrmid for long-term growth.

**【Q&A Key Takeaways】**
- **Asset Evaluation Progress:** Multiple early-stage oncology/rare disease assets in due diligence, with >70% focus on oncology.
- **PDAC Trial Expectations:** Interim analysis in 2026; potential to address $2B+ pancreatic cancer market.
- **APHEXDA Market Education:** Ayrmid leveraging existing transplant network, with no direct BioLineRx commercial involvement post-transition.

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

- **APHEXDA Commercial Momentum**: 20% of U.S. transplant centers using APHEXDA, targeting 60% by year-end. China bridging study IND filed, first patient dosed H2 2024.
- **Pancreatic Cancer Trial Progress**: Phase 2b trial (N=108) first patient dosed, 91% disease control rate in pilot phase.
- **Financial Position**: $4.8M 2023 revenue, $60.6M net loss, $43M cash on hand.
- **Strategic Collaborations**: Gloria Biosciences advancing APHEXDA in Asia, Wash U evaluating motixafortide for sickle cell gene therapy.

**【CEO Opening Remarks】**
- Launched APHEXDA in Q4 2023, with early momentum in U.S. stem cell mobilization market. 
- Secured formulary placement in top 80 transplant centers managing 20% of procedures, targeting 60% by year-end.
- Progressing APHEXDA commercialization in Asia via Gloria Biosciences, with IND filed for China bridging study.

**【President of BioLineRx USA (Holly May) - Stem Cell Mobilization Update】**
- 95% of covered lives have APHEXDA access across commercial and government payers.
- Formulary approvals expected to expand to 35% of procedures by Q2 and 60% by year-end.
- APHEXDA's differentiated profile (stronger mobilization, reduced apheresis days) resonates with transplant centers despite generic plerixafor competition.

**【CEO Clinical Program Update】**
- Pancreatic cancer Phase 2b trial (N=108) with Columbia/Regeneron: 91% disease control rate in pilot phase, first patient dosed in Q1 2024.
- Sickle cell disease collaboration with Washington University: Phase 1 trial evaluating motixafortide for hematopoietic stem cell mobilization, first patient dosed in Q4 2023.

**【CFO Financial Commentary】**
- 2023 Revenue: $4.8M (all Q4), driven by $4.6M from Gloria license and $0.2M product sales.
- Net loss: $60.6M (includes $17.8M non-cash expenses).
- Cash balance: $43M as of Dec 31, 2023, sufficient for operations into 2025.

**【Q&A Highlights】**
- Formulary process: Takes 3-6 months, varies by institution; 20% of centers have fully transitioned to APHEXDA.
- Gene therapy opportunities: Exploring collaborations for motixafortide in ex-vivo stem cell gene therapies beyond sickle cell disease.
- Asia expansion: Gloria targeting commercialization in Singapore, Macau, and China's Bao region in H2 2024.

Actual												-29.9999	-18	-12	-22.914	-12	-6	-6	0	-6	-6	-6	-3.618	-6	-12	-12	-7.638	0	0	0	-1.6	0	0	0	-0.385
Forecast												-33.1649	-24.12	-14.472	-9.782	-7.504	-4.623	-5.025	-5.628	-6.03	-5.226	-6.633	-5.427	-5.628	-6.834	-8.442	-8.844	-11.658	-3.015	-1.742	-0.8073	-0.95	-0.3533	-0.67	-0.385
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+9.54%	+25.37%	+17.08%	-134.25%	-59.91%	-29.79%	-19.40%	+100.00%	+0.50%	-14.81%	+9.54%	+33.33%	-6.61%	-75.59%	-42.15%	+13.64%	+100.00%	+100.00%	+100.00%	-98.19%	+100.00%	+100.00%	+100.00%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.80M	6.90M	5.39M	4.94M	11.75M	255.00K	304.00K	427.00K	514.00K
Forecast	--	--	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	150.00K	340.00K	3.93M	5.29M	7.72M	1.48M	661.33K	990.00K	514.00K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3100.00%	+1929.41%	+37.23%	-6.57%	+52.22%	-82.78%	-54.03%	-56.87%	0.00%

BLRX

BLRX fundamentals

BLRX Q4 2025 Earnings

Earnings Call

You can ask Aime

BLRX

BLRX fundamentals

BLRX Q4 2025 Earnings

Earnings Call

BLRX Earnings Call Summary for Q4/20258:30 AM on Mar 23, 2026

BLRX Earnings Call Summary for Q3/20258:30 AM on Nov 24, 2025

BLRX Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

BLRX Earnings Call Summary for Q1/20258:30 AM on May 27, 2025

BLRX Earnings Call Summary for Q4/20248:30 AM on Mar 31, 2025

You can ask Aime